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doi:10.1Objective: Axillary intra-aortic balloon pump therapy has been described as a bridge to transplant. Advantages
over femoral intra-aortic balloon pump therapy include reduced incidence of infection and enhanced patient mo-
bility. We identified the patients who would benefit most from this therapy while awaiting heart transplantation.
Methods: We conducted a single-center, retrospective observational study to evaluate outcomes from axillary
intra-aortic balloon pump therapy. These included hemodynamic parameters, duration of support, and success in
bridging to transplant. We selected patients on the basis of history of sternotomy, elevated panel-reactive anti-
body, and small body habitus. Patients were made to ambulate aggressively beginning on postoperative day 1.
Results: Between September 2007 and September 2010, 18 patients underwent axillary intra-aortic balloon
pump therapy. All patients had the devices placed through the left axillary artery with a Hemashield side graft
(Boston Scientific, Natick, Mass). Before axillary placement, patients underwent femoral placement to demon-
strate hemodynamic benefit. Duration of support ranged from 5 to 63 days (median ¼ 19 days). There was
marked improvement in ambulatory potential and hemodynamic parameters, with minimal blood transfusion
requirements. There were no device-related infections. Some 72% of the patients (13/18) were successfully
bridged to transplantation.
Conclusions: Axillary intra-aortic balloon pump therapy provides excellent support for selected patients as
a bridge to transplant. The majority of the patients were successfully bridged to transplant and discharged. Al-
though this therapy has been described in previous studies, this is the largest series to incorporate a regimen of ag-
gressive ambulation with daily measurements of distances walked. (J Thorac Cardiovasc Surg 2012;143:1193-7)T
XCardiac transplantation is currently the definitive therapy
for patients with end-stage heart failure. However, the avail-
ability of donor hearts to perform transplantation remains
a major limiting factor. The United Network for Organ
Sharing Registry data show the number of available hearts
to range from 3000 to 3500 over the last several years.1
With an increasing number of patients developing end-
stage heart failure each year, the number awaiting cardiac
transplantation far exceeds the number of available donor
hearts.
As a result, mechanical support devices have been used
increasingly as a bridge-to-transplant strategy to sustain pa-
tients’ hemodynamics and organ function while they are on
the heart transplant waiting list. Specific hemodynamic
criteria are applied when the use of mechanical support ise Vanderbilt Heart and Vascular Institute, Nashville, Tenn.
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The Journal of Thoracic and Carconsidered. These criteria include a cardiac index of less
than 2.2 L/min/m2, systolic blood pressure of less than 90
mm Hg, mean pulmonary capillary wedge pressure or cen-
tral venous pressure of greater than 20mmHg, and concom-
itant use of high doses of at least 2 inotropic agents.1 A
patient’s initial decline in hemodynamic status may first
be managed pharmacologically with inotropes and an
intra-aortic balloon pump (IABP), which is usually percuta-
neously inserted via the femoral artery. Although a femoral
IABP can be inserted with relatively low risk and ease, ma-
jor disadvantages include risk of infection, limited duration
of support (3–7 days), and severe restriction of a patient’s
mobility. This constraint further deconditions a patient’s
musculoskeletal system. Insertion of an IABP via the axil-
lary artery overcomes these disadvantages, and patients
are able to ambulate.
Although there are a multitude of intermediate and long-
term circulatory support devices available, the implantation
of these devices can be costly financially and physiologi-
cally. In certain patients, the surgical risk may be high
because of multiple previous cardiac surgeries. Some pa-
tients may also present with issues that render the use of
these devices difficult, including the inability to tolerate
higher levels of anticoagulation, history of sternotomies,
elevated panel-reactive antibody (PRA) levels, or smalldiovascular Surgery c Volume 143, Number 5 1193
TABLE 1. Patient characteristics
Variables Patients (n ¼ 18)
Median age (y) 56 (20–64)
Gender
Male 15/18 (93%)
Female 3/18 (17%)
BMI (m2/kg) 25.55 (19.66–33.22)
Diabetes 7/18 (39%)
Hypertension 7/18 (39%)
COPD (moderate to severe) 3/18 (16.7%)
Creatinine 1.5 mg/dL at the time of
IABP insertion
7/18 (39%)
Chronic renal failure on hemodialysis 1/18 (5.6%)
Inotropic support 18/18 (100%)
Median ejection fraction (%) 15 (5–25)
Congestive heart failure 18/18 (100%)
Mean NYHA class Class IV
Carotid artery disease with>75% stenosis 3/18 (16.7%)
Prior myocardial infarction 3/18 (16.7%)
Atrial fibrillation 7/18 (39%)
Previous sternotomy or elevated PRA (>20%)
or small body habitus (BMI<25)
10/18 (56%)
Ischemic cardiomyopathy 9/18 (50%)
Dilated cardiomyopathy 9/18 (50%)
Mitral insufficiency (moderate to severe) 7/18 (39%)
Tricuspid insufficiency (moderate to severe) 5/18 (27.8%)
Values presented as mean, median (range), or number (percent). BMI, Body mass
index; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon
pump; NYHA, New York Heart Association; PRA, panel-reactive antibody.
Abbreviations and Acronyms
BTT ¼ bridge to transplant
IABP ¼ intra-aortic balloon pump
LVAD ¼ left ventricular assist device
PRA ¼ panel-reactive antibody
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Xbody habitus, which could make implantation difficult. The
patient may have psychosocial issues that preclude the use
of a left ventricular assist device (LVAD). Axillary IABP
counterpulsation therapy is an alternate strategy in these
scenarios, providing a feasible bridge-to-transplant option
while maintaining patient mobility. In addition to contain-
ing cost, axillary IABP therapy also provides several other
advantages compared with standard LVAD therapy. It is
a less complicated surgical procedure with shorter extuba-
tion times and reduced blood transfusion requirements,
and does not require specialized infrastructure and person-
nel for care as LVAD therapy does. Other distinct advan-
tages with axillary IABP therapy include a low incidence
of device-related infections, postoperative bleeding, stroke,
and thrombosis.
We report our experience over a 2-year period in which
axillary IABP support was used in 18 patients as a bridge
to transplant (BTT). The patients underwent axillary
IABP placement in our hybrid operating room, which com-
bines the facilities of a cardiac surgery operating room with
a cardiac catheterization laboratory.MATERIALS AND METHODS
We conducted a retrospective review of the first 18 patients in whom left
axillary IABPs were placed between September 2007 and 2010 at the
Vanderbilt Heart Institute after obtaining institutional review board ap-
proval. All patients undergoing axillary IABP insertion had end-stage heart
failure and failed ongoing inotropic support or could not tolerate inotropic
therapy because of arrhythmias from the inotropes. We specifically identi-
fied patients with a history of sternotomy, elevated PRA (>20%), or small
body habitus (body mass index<25). Before selection for axillary IABP
placement, patients underwent femoral balloon placement to establish he-
modynamic benefit from counterpulsation therapy ranging from improved
cardiac output and reduced pulmonary artery pressures.
Our management plan was to wean the femoral IABP, and if this was
tolerated, the femoral IABP was taken out the same day before axillary
IABP insertion. If the wean was not tolerated, then the wire was already
in place for the axillary IABP before taking out the femoral IABP in the
operating room. We were cautious in ascertaining that the hemodynamic
benefit from the axillary IABP was similar to the femoral test insertion.
All patients were brought to the operating room, and monitoring lines
were placed. Preoperative intravenous prophylactic antibiotics were given.
After induction, the patient was prepped and draped in the standard fashion.
An incision was made below the left clavicle. The fibers of pectoralis major
and minor were split. The fascia was then incised with Metz scissors.
Vessel loops were placed around the axillary vein and artery. Heparin
was given, and the axillary artery was clamped proximally and distally.
An appropriate arteriotomy was made, and a 6-mm Hemashield graft
(Boston Scientific, Natick, Mass) was sewn with 5-0 running Prolene.
The graft was allowed to back-bleed, and good hemostasis was achieved.1194 The Journal of Thoracic and Cardiovascular SurThe free end of the graft was shortened and oversewn with running 5-0
Prolene suture.
A pledgeted purse-string with 5-0 Prolene was placed on the anterior
surface of the graft. A needle was placed in the center of the purse-
string, and the balloon wire was advanced. This was done using
fluoroscopy.
The entry site was successively dilated. Once the wire was confirmed to
be in the descending aorta, the IABP was advanced over the wire into the
descending aorta. Care was taken to flush and de-air the lines. The IABP
was initiated, and positioning was reconfirmed by transesophageal
echocardiography.
After confirmation of hemostasis, the axillary incision was closed in
layers. The stump of the graft was placed superficial to the pectoralis major
fascia. The skin was approximated with running Monocryl suture. The
IABP was secured to the skin.
Patients were returned to the cardiovascular intensive care unit in stable
condition. Aggressive ambulatory therapy was initiated from the first post-
operative day. Parameters such as cardiac index, mean and systolic pulmo-
nary artery pressures, central venous pressure, and maximum distance
ambulated daily were recorded and compared with their respective values
pre-IABP placement. Time to extubation, blood transfusion requirements,
and changes in creatinine were also recorded. The duration of support on
the IABP and time to cardiac transplant (as appropriate) were recorded.
A 2-tailed paired t test was used for statistical comparison of pre- and
post-IABP parameters.RESULTS
Between September 2007 and 2010, 18 patients were
managed with axillary IABP therapy at the Vanderbilt Heartgery c May 2012
TABLE 2. Perioperative data
Pre-IABP
n ¼ 18
Post-IABP
n ¼ 18 P value Percent improvement
CI 1.91  0.48 2.84  0.70 <.001 49
PA systolic 54.65  17.77 45.60  11.89 .025 17
PA mean 38.82  12.40 31.07  9.35 .009 20
CVP 24.12  8.44 12.65  5.93 <.001 48
Longest distance walked/day (ft) 411.4  247.7 2654.58  2425.52 .008 545
PRBC 24 h postoperatively 0.11  0.32
Time to extubation in hours 0.64  1.65
Survival
1 mo 16/18 (89%)
6 mo 13/18 (72%)
No. transplanted 13/18 (72%)
Days to transplant 26.7  17.7
Median: 19
Range: 5–63
Values presented as mean (standard deviation), median (range), or number (percent). IABP, intra-aortic balloon pump; CI, cardiac index; PA, pulmonary artery; CVP, central
venous pressure; PRBC, packed red blood cells.
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1. Fifty percent of the patients presented with ischemic car-
diomyopathy, and 50% of the patients presented with
dilated cardiomyopathy. Fifty-six percent of the patients
(10/18) had a history of sternotomy or elevated PRA levels
(>20%) or small body habitus (body mass index<25).
All patients had ambulatory IABPs successfully placed
through the left axillary route. The median time to extuba-
tion was 0.64  1.65 hours. Sixty-seven percent (12/18) of
the patients were extubated in the operating room.
After axillary IABP placement, there was significant he-
modynamic response (Table 2). Specifically, we observed
improvements in cardiac index (2.84  0.70 post-IABP vs
1.91 0.48 pre-IABP, P ¼ .001), decrease in mean pulmo-
nary arterial pressure (31.1 9.4 mmHg post-IABP vs 38.8
 12.4 mmHg pre-IABP, P¼ .009), and decrease in central
venous pressure (12.7  5.9 mm Hg post-IABP vs 24.1 
8.4 mm Hg pre-IABP, P ¼ .001). The duration ofTABLE 3. Adverse events
Complication Patients (n ¼ 18)
IABP-related infection 0/18 (0%)
IABP failure 3/18 (17%)
Migration 1/18 (5.6%)
Kinking 1/18 (5.6%)
Rupture 1/18 (5.6%)
Mortality before transplantation 5/18 (27.8%)
Multisystem organ failure from pulmonary
infection
2/18 (11.2%)
Myocardial infarction 1/18 (5.6%)
Progressive heart failure 1/18 (5.6%)
Cardiac arrest 1/18 (5.6%)
IABP-related vascular complication 0/18 (0%)
Stroke 0/18 (0%)
Other miscellaneous complications 0/18 (0%)
Values presented as number (percent). IABP, intra-aortic balloon pump.
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T
Xambulatory IABP support ranged from 5 to 63 days (26.7
 17.7 days), and the duration of time to transplant was
26.7  17.7 days. The longest distance walked in a day
was 2654.58  2425.52 feet post-IABP vs 411.4  247.7
feet pre-IABP (P ¼ .008). The majority of patients (72%,
13/18) underwent successful cardiac transplantation and
were discharged from the hospital.
Major complications of axillary IABP support in this se-
ries are shown in Table 3. Three patients required IABP re-
placement because of device migration, kinking, and
rupture. There were no deaths in this group. Mean blood
transfusion requirement 24 hours after IABP placement
was 0.11 0.32 units. Only 2 patients in the series required
blood transfusions. Five patients died on axillary IABP sup-
port while waiting for cardiac transplant. Two patients died
of multisystem organ failure secondary to pulmonary infec-
tion, 1 patient died of a massive myocardial infarction, 1 pa-
tient died of progressive heart failure, and 1 patient died of
cardiac arrest. Figures 1 and 2 show bar graph comparisons
of pre-IABP and post-IABP cardiac index and comparisons
of longest distance walked in 1 day.DISCUSSION
In our experience, we found that axillary IABP therapy in
selected patients provides hemodynamic support, maintains
excellent mobility, and has a BTT rate of 72%. It is a less
complicated surgical procedure with a shorter period of
ventilator support and reduced blood transfusion require-
ments. It is specifically useful in patients with a history of
sternotomy, elevated PRA, and small body habitus. In addi-
tion, there is a low incidence of device-related infections,
postoperative bleeding, stroke, and thrombosis. Axillary
IABP therapy should be considered in the armamentarium
for strategic mechanical circulatory support in appropri-
ately selected patients.diovascular Surgery c Volume 143, Number 5 1195
 P <0.001
Pre-IABP Post-IABP
FIGURE 1. Bar graph comparison of pre-IABP and post-IABP cardiac
index. IABP, Intra-aortic balloon pump.
FIGURE 2. Bar graph comparison of longest distance walked in 1 day
(in feet) pre-IABP and post-IABP. IABP, Intra-aortic balloon pump.
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XThe incidence of end-stage heart failure continues to in-
crease, whereas the availability of donor hearts remains
a fixed resource. Because of the shortage of donor hearts,
alternate solutions have been pursued for hemodynamic sta-
bilization and optimization. The literature shows implanta-
tion of a ventricular assist device as BTT has significant
risks, such as postoperative bleeding, stroke, blood transfu-
sions, and drive-line infections leading to sepsis. In addi-
tion, the financial costs of ventricular assist device
therapy should be considered, especially in the current era
of cost-consciousness. Therefore, cost containment, effi-
cacy, and postoperative complications of mechanical sup-
port must be considered in BTT. Future studies will be
necessary to assess axillary IABP strategy in the context
of ventricular assist device therapy.
The first insertion of the IABP via the axillary approach
was described by McBride and colleagues2 in 1989. There-
after, H’Doubler and colleagues3 published the largest
series in 2000 consisting of 13 patients who underwent
axillary IABP therapy over the course of a 3-year period.
Of these, 10 patients were successfully bridged to transplant
with duration of IABP support ranging from 10 to 86 days.
Subsequently in 2002, Cochran and colleagues4 published
the results of their series on 4 patients who underwent
axillary IABP therapy over the course of a 1.5-year period.
All patients were successfully bridged to transplant, and the
duration of IABP support ranged from 12 to 70 days.
Our series, the largest so far, indicates that ambulatory
IABPs placed via the axillary route in selected patients pro-
vide excellent support as BTTwithout hindering mobility in
selected patients. It also demonstrates that aggressive ambu-
latory therapy initiated promptly after axillary IABP inser-
tion can prove to be of tremendous benefit. There were no
device-related infections or bleeding or embolic complica-
tions. Patients were extubated in the operating room or on
arrival to the cardiovascular intensive care unit without
any complications. There were 5 mortalities, and these
were not device related. There were no complications
involving the axillary artery or the left upper extremity.1196 The Journal of Thoracic and Cardiovascular SurOf these mortalities, the 1 patient who subsequently
received biventricular support was a complex case. In
addition to heart failure, this patient had a severe lower-
extremity infection, and we were hoping to control this in-
fection and avoid implantation of excess hardware. As the
patient’s condition worsened from a circulatory standpoint,
we had to increase the level of support. If this patient did not
have lower-extremity cellulites, he would have gone
straight to long-term mechanical support. This patient was
transitioned to a biventricular assist device but ultimately
died as the result of worsening of infection and subsequent
pulmonary infection-related multisystem organ failure. A
second patient requested removal of circulatory support
and subsequently died of heart failure. A third patient
died with subsequent pulmonary infection and multisystem
organ failure after the family decided to withdraw care by
the family. A fourth patient died after nonischemic cardio-
myopathy resulting from a massive myocardial infarction.
The fifth patient died of sudden arrhythmia and cardiac ar-
rest. All mortalities also occurred in cases of nonischemic
cardiomyopathy. Thus, the benefit of this technique in non-
ischemic patients may be less than in ischemic patients. In
general, our criteria were to use this less-invasive technique
of axillary IABP placement in patients who have demon-
strated benefit from femoral IABP placement. If we ob-
served that the axillary IABP did not improve the indices
of perfusion and hemodynamic parameters, the plan was
to transition to ventricular assist device support. As men-
tioned, only 1 patient required transition to ventricular assist
device support.
All the mortalities were in nonischemic patients. Thus,
our study seems to also indicate that this technique is
more beneficial in ischemic patients. This may be a reflec-
tion of nonischemic patients receiving intervention at
a physiologically worse point on their heart failure curve.
This warrants further investigation.
There are many advantages to an ambulatory axillary
IABP therapy over LVAD placement. In addition to reducedgery c May 2012
Umakanthan et al Cardiothoracic Transplantationdevice-related infections, stroke, thrombosis, postoperative
bleeding, blood transfusion requirements, extubation times,
and cost, the placement of an axillary IABP is a simpler pro-
cedure. Because the transfusion requirements are essentially
nonexistent for IABPplacement, the risk of increasing PRAs
is virtually zero from the procedure. Moreover, Cochran and
colleagues4 showed no evidence of elevated PRAs second-
ary to long-term IABP therapy.
Unlike LVAD insertion, placement of an axillary IABP
does not require cardiopulmonary bypass or expose the
patient to an additional sternotomy before heart transplanta-
tion. In addition, the removal of the axillary IABP is
a relatively simple procedure at the time of cardiac trans-
plantation. Furthermore, the axillary IABP also provides
support while weaning from cardiopulmonary bypass.
LVAD removal can be potentially difficult with bleeding
complications. There were no thromboembolic events or
any incidents of platelet dysfunction noted as a result of
axillary IABP therapy in our series.
Every heart center has an ancillary infrastructure and per-
sonnel who are well versed in the management of an IABP.
Excellent nursing experience with IABP management is
well established in cardiac units. Therefore, expanding its
use to the telemetry unit can be considered.
Study Limitations
Study limitations include that this was not a randomized
prospective evaluation of the technology. In addition, the
nutritional status of patients when they are bridged to
transplant after axillary IABP placement was not evaluated.The Journal of Thoracic and CarAxillary IABP therapy has the limitation of requiring a pro-
longed intensive care unit stay. This constraint could be
mitigated with appropriate training of the personnel and in-
frastructure in the step-down unit.
CONCLUSIONS
Our data show that axillary IABP therapy is an excellent
means of conferring hemodynamic support in well-selected
patients with end-stage heart failure with a successful BTT
rate of 72%. The axillary IABP enables patients’ ambula-
tion and optimization of rehabilitation potential. The axil-
lary IABP improves hemodynamics and right ventricular
performance, which may reduce the need for right ventric-
ular assist device support during LVAD insertion if the pa-
tient does not receive a donor heart during the extended
hospitalization. Clearly, future investigations will be neces-
sary to determine optimal use of the axillary IABP in select-
ing patients for BTT versus the subset who do not receive
transplants but become better candidates for LVAD therapy
after optimization of right ventricular hemodynamics.References
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